Relapse/Refractory Lymphomas research hub

BiCAR Therapy - A Phase II Trial Evaluating Glofitamab, a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas after CAR T-cells therapy

This study is looking at a new medicine called glofitamab for people with lymphoma that has come back or hasn't responded to previous treatments, including CAR T-cell therapy. It's in an early stage of testing to see how well it works and if it helps people live longer.